Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06128148
Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors
- NCT06128148 ↗
- Recruiting
- Guangzhou JOYO Pharma Co., Ltd
- Focused
We haven't built an HCP commentary report on NCT06128148 (JYP0322 in ROS1 fusion-positive solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06128148 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of JYP0322 in Patients With Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Protein Kinase Inhibitors; Other Protocol Specified Criteria; Lung Neoplasms; Brain Neoplasms
- Interventions
- JYP0322 50 mg qd; JYP0322 100 mg qd; JYP0322 200 mg qd; JYP0322 100 mg bid; JYP0322 150 mg bid; JYP0322 200 mg bid; JYP0322 150mg tid
- Arms
- 50 mg qd · Experimental
- 100 mg qd · Experimental
- 200 mg qd · Experimental
- 100 mg bid · Experimental
- 150 mg bid · Experimental
- 200 mg bid · Experimental
- 150 mg tid · Experimental
- Enrollment
- 101 (estimated)
- Primary outcomes
- The frequency and severity of adverse events of JYP0322
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
- Start
- May 4, 2022
- Primary completion
- Jun 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06128148 · updated Jul 14, 2025